1-1 2020 version TUOA 攝護腺癌指引.pdf
1-2 台灣泌尿腫瘤醫學會 RCC guideline 2020版.pdf
1-3 TUOA_UC治療指引.pdf
1-4 TUOA_膀胱癌.pdf
2-1 Taxotere-PC.pdf
2-2 PC_Abiraterone.pdf
2-3 Enzalutamide_20200115.pdf
2-4 20200210 更新_PC-Radium223 Xofigo.pdf
2-5 PC_Denosumab.pdf
2-6 PC_Degarelix.pdf
2-7 PC_Goserelin.pdf
2-8 PC_Leuprorelin.pdf
2-9 PC_Eligard_2020.pdf
3-1 RCC_Sutent仿單資料整理.pdf
3-2 RCC_Torisel 仿單資料整理.pdf
3-3 RCC_Pazopanib.pdf
3-4 RCC_Inlyta仿單資料整理.pdf
3-5 RCC_Everolimus.pdf
3-6 RCC_Sorafenib.pdf
3-7 Cabozantinib RCC TUOA Guidelines.pdf
Bacillus Calmette-Guerin
5-1 Immune_Pembrolizumab 2020.pdf
5-2 Immune_Nivolumab 2020.pdf
5-3 Immune-Atezolizumab.pdf
5-4 Durvalumab Imfinzi.pdf
5-5 Bavencio+Axitinib in RCC_Merck.pdf
